"It is important to show to the government the economic relevance of clinical research since it represents one of the main areas of investment of pharmaceutical…
In Conversation
Pius Hornstein, MSc, PhD, country chair Sanofi Brazil and general manager Pharma, shares his positive outlook on the Brazilian pharma market over the next few years…
We have chosen Switzerland for several reasons: a stable political and economic environment, the fact many Big Pharma companies have offices there, the strong network of…
"Our vision is to integrate the top 52 companies in Brazil within the next five years and to double our operating income in the meantime."
"Never in the history of Quebec have we invested so much in research and innovation. Over the next five years, CAD 2.8 billion will be poured…
"As ABIQUIFI, we are now working closely with the government and regulatory authorities to change the country’s paradigm in this regard and – for example -…
FIRM acts as a form of translational bridge between academia and the market, bringing the results of academia to the patient
The most important item, these past five years, has been winning the trust of the public, the industry and academia alike
"India is part of the cluster of high growth markets in the APAC region and it is growing very fast, not only in terms of population…
"Our evolution in Canada has been quite successful and I think we have been able to demonstrate that we are committed and here to stay."
"Despite the difficulties associated with bringing new products to the market in Brazil, we have successfully launched six new products these years."
"Our fundamental goal is to make a difference for our customers. We do this mainly by launching new and innovative generics products where there is significant…
